Study results from the Clinical Trials Network's first 10 years: Where do they lead?

Journal of Substance Abuse Treatment

Volumn 38, Issue SUPPL. 1, 2010, Pages

  Wells, Elizabeth A ^a   Saxon, Andrew J ^b,c   Calsyn, Donald A ^c   Jackson, Thomas R ^a,d   Donovan, Dennis M ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Evergreen Treatment Services   (United States)

Author keywords

Clinical trials; Effectiveness research; Substance abuse treatment

Indexed keywords

AMFEBUTAMONE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; METHADONE; NICOTINE; NICOTINE PATCH; VARENICLINE;

ARTICLE; BEHAVIOR THERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMMUNITY CARE; COUNSELING; DETOXIFICATION; DOSAGE SCHEDULE COMPARISON; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MOTIVATION; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; PATIENT COMPLIANCE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PSYCHOSOCIAL CARE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

CLINICAL TRIALS AS TOPIC; HUMANS; NATIONAL INSTITUTE ON DRUG ABUSE (U.S.); QUALITY ASSURANCE, HEALTH CARE; RESEARCH DESIGN; RISK-TAKING; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME; UNITED STATES;

EID: 77950266759     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2009.12.009     Document Type: Article

References (52)

1. Ball S.A., Martino S., Nich C., Frankforter T.L., Van Horn D., Crits-Christoph P., et al. Site matters: Multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. Journal of Consulting and Clinical Psychology 2007, 75:556-567. for the NIDA CTN.
2. Brown L.S., Kritz S.A., Goldsmith R.J., Robinson J., Alderson D., Rotrosen J. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs. Public Health Reports 2007, 122:441-451.
3. Calsyn D.A., Hatch-Maillette M., Tross S., Doyle S.R., Crits-Christoph P., Song Y.S., et al. Motivational and skills training HIV/sexually transmitted infection sexual risk reduction groups for men. Journal of Substance Abuse Treatment 2009, 37:138-150.
4. Campbell B.K., Fuller B.E., Lee E.S., Tillotson C., Woelfel T., Jenkins L., et al. Facilitating outpatient treatment entry following detoxification for injection drug use: A multisite test of three interventions. Psychology of Addictive Behaviors 2009, 23:260-270.
5. Carroll K.M., Ball S.A., Nich C., Martino S., Frankforter T.L., Farentinos C., et al. Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: A multisite effectiveness study. Drug and Alcohol Dependence 2006, 81:301-312. for the NIDA CTN.
6. Carroll K.M., Martino S., Suarez-Morales L., Ball S.A., Miller W.R., et al. A multisite randomized effectiveness trial of motivational enhancement for spanish-speaking substance users. Journal of Consulting and Clinical Psychology 2009, 77(5):993-999.
7. Carroll K.M., Onken L.S. Behavioral therapies for drug abuse. American Journal of Psychiatry 2005, 162:1452-1460.
8. Carroll K.M., Rounsaville B.J. Bridging the gap: A hybrid model to link efficacy and effectiveness research in substance abuse treatment. Psychiatric Services 2003, 54:333-339.
9. Chambless D.L., Crits-Christoph P. The treatment method. Evidence-based practices in mental health: Debate and dialogue on the fundamental questions 2006, 191-199. American Psychological Association, Washington, D.C. J.C. Norcross, L.E. Beutler, R.F. Levant (Eds.).
10. DesJarlais D.C., Semaan S. HIV prevention for injecting drug users: The first 25 years and counting. Psychosomatic Medicine 2008, 70:606-611.
11. Ducharme L.J., Knudsen H.K., Roman P.M., Johnson J.A. Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment 2007, 32:321-329.
12. Eisenberger R., Cameron J. Detrimental effects of reward: Reality or myth?. American Psychologist 1996, 51:1153-1166.
13. Fiore M.C., Jaén C.R., Baker T.B., et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline 2008, U.S. Departmentof Health and Human Services. Public Health Service, Rockville, MD.
14. Forman R.F., Crits-Christoph P., Kaynak O., Worley M., Hantula D.A., Kulaga A., et al. A feasibility study of a Web-based performance improvement system for substance abuse treatment providers. Journal of Substance Abuse Treatment 2007, 33:363-371.
15. Glasgow R.E. What types of evidence are most needed to advance behavioral medicine?. Annals of Behavioral Medicine 2008, 35:19-25.
16. Greenfield S.F., Brooks A.J., Gordon S.M., Green C.A., Kropp F., McHugh R.K., et al. Substance abuse treatment entry, retention, and outcome in women: A review of the literature. Drug and Alcohol Dependence 2007, 86:1-21.
17. Hall S.H., Munoz R.F., Reus V. Cognitive-Behavioral intervention increases abstinence rates for depressive-history smokers. Journal of Consulting and Clinical Psychology 1994, 62:141-146.
18. Hays J.T., Ebbert J.O. Varenicline for tobacco dependence. New England Journal of Medicine 2008, 359:2018-2024.
19. Hien D.A., Cohen L.R., Miele G.M., Litt L.C., Capstick C. Promising treatments for women with comorbid PTSD and substance use disorders. American Journal of Psychiatry 2004, 161:1426-1432.
20. Hien D.A., Wells E.A., Jiang H., Suarez-Morales L., Campbell A., Cohen L., et al. Multi-site randomized trial of behavioral interventions for women with co-occurring PTSD and substance use disorders. Journal of Consulting and Clinical Psychology 2009, 77:607-619.
21. Hubbard R.L., Leimberger J.D., Haynes L., Patkar A.A., Holter J., Liepman M.R., et al. Telephone enhancement of long-term engagement (TELE) in continuing care for substance abuse treatment: A NIDA Clinical Trials Network (CTN) study. American Journal on Addictions 2007, 16:495-502.
22. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. New England Journal of Medicine 1999, 340:685-691.
23. Knudsen H.K., Ducharme L.J., Roman P.M. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment 2006, 30:363-373.
24. Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment 1998, National Academy Press, Washington, DC. S. Lamb, M.R. Greenlick, D. McCarty (Eds.).
25. Lash S.J., Stephens R.S., Burden J.L., Grambow S.C., DeMarce J.M., Jones M.E., et al. Contracting, prompting, and reinforcing substance use disorder continuing care: A randomized clinical trial. Psychology of Addictive Behaviors 2007, 21:387-397.
26. Lavori P.W., Dawson R. Adaptive treatment strategies in chronic disease. Annual Review of Medicine 2008, 59:443-453.
27. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings for the National Institute on Drug Abuse Clinical Trials Network. Addiction 2005, 100:1090-1110. the Buprenorphine Study Protocol Group.
28. Ling W., Hillhouse M., Domier C., Doraimani G., Hunter J., Thomas C., et al. Buprenorphine tapering schedule and illicit opioid use. Addiction 2009, 104:256-265.
29. Martino S., Ball S.A., Nich C., Frankforter T.L., Carroll K.M. Informal discussions in substance abuse treatment sessions. Journal of Substance Abuse Treatment 2009, 36:366-375.
30. McCarty D., Fuller B.W., Wendt W.W., Nunes E.V., Magruder K.M., Arfken C.L., et al. Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. Drug and Alcohol Dependence 2008, 92:200-207.
31. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence, a chronic medical illness: Implications for treatment insurance, and outcomes evaluation. Journal of the American Medical Association 2000, 284:1693.
32. Miller W.R., Zweben J., Johnson W.R. Evidence-based treatment: Why, what, where, when, and how?. Journal of Substance Abuse Treatment 2005, 29:267-276.
33. Murphy S.A., Lynch K.G., Oslin D., McKay J.R., TenHave T. Developing adaptive treatment strategies in substance abuse research. Drug and Alcohol Dependence 2007, 88(Suppl 2):S24-S30.
34. Najavits L.M. Seeking safety: A treatment manual for PTSD and substance abuse 2002, Guilford, New York.
35. National Institute on Drug Abuse Principles of drug addiction treatment: A research based guide 1999, National Institute on Drug Abuse, Bethesda, MD.
36. Evidence-based practices in mental health: Debate and dialogue on the fundamental questions 2006, American Psychological Association, Washington, D.C. J.C. Norcross, L.E. Beutler, R.F. Levant (Eds.).
37. Norcross J.C., Lambert M.J. The therapy relationship. Evidence-based practices in mental health: Debate and dialogue on the fundamental questions 2006, 208-217. American Psychological Association, Washington, D.C. J.C. Norcross, L.E. Beutler, R.F. Levant (Eds.).
38. Ollendick T.H., King N.J. Empirically supported treatments typically produce outcomes superior to non-empirically supported treatment therapies. Evidence-based practices in mental health: Debate and dialogue on the fundamental questions 2006, 308-316. American Psychological Association, Washington, D.C. J.C. Norcross, L.E. Beutler, R.F. Levant (Eds.).
39. Peirce J.M., Petry N.M., Stitzer M.L., Blaine J., Kellogg S., Satterfield F., et al. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment. Archives of General Psychiatry 2006, 63:201-208.
40. Petry N.M. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug and Alcohol Dependence 2000, 58:9-25.
41. Petry N.M., Peirce J.M., Stitzer M.L., Blaine J., Roll J.M., Cohen A., et al. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs. Archives of General Psychiatry 2005, 62:1148-1156.
42. Reid M.S., Fallon B., Sonne S., Flammino F., Nunes E.V., Jiang H., et al. Smoking cessation treatment in community-based substance abuse rehabilitation programs. Journal of Substance Abuse Treatment 2008, 35:68-77.
43. Rotrosen J., Leshner A.I., Tai B., Greenlick M.R., Pencer E., Trachtenberg R., et al. The National Drug Abuse Treatment Clinical Trials Network-Challenges and opportunities. Problems in Drug Dependence., 2001: Proceedings of the 63rd Annual Scientific Meeting, The College on Problems in Drug Dependence. NIDA Research Monograph 182 2002, 12-17. National Institute on Drug Abuse, Bethesda, MD. L.S. Harris (Ed.).
44. Rounsaville B.J., Carroll K.M., Onken L.S. A stage model of behavioral therapies research: Getting started and moving on from Stage I. Clinical Psychology: Science and Practice 2001, 8:133-142.
45. Saxon A.J., McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology & Therapeutics 2005, 108:119-128.
46. Schwartz B. The creation and destruction of value. American Psychologist 1990, 45:7-15.
47. Treweek S., Zwarenstein M. Making trials matter: Pragmatic and explanatory trials and the problem of applicability. Trials 2009, 10:37.
48. Tross S., Campbell A.N.C., Cohen L.R., Calsyn D., Pavlicova M., Miele G.M., et al. Effectiveness of HIV/STD sexual risk reduction groups for women in substance abuse treatment programs: Results of NIDA Clinical Trials Network trial. Journal of Acquired Immune Deficiency Syndromes 2008, 48:581-589.
49. Walker R. Retention in treatment-Indicator or illusion: An essay. Substance Use and Misuse 2009, 44:18-27.
50. Wampold B.E. Not a scintilla of evidence to support empirically supported treatments as more effective than other treatments. Evidence-based practices in mental health: Debate and dialogue on the fundamental questions 2006, 299-307. American Psychological Association, Washington, D.C. J.C. Norcross, L.E. Beutler, R.F. Levant (Eds.).
51. Winhusen T., Kropp F., Babcock D., Hague D., Erickson S.J., Renz C., et al. Motivational enhancement therapy to improve treatment utilization and outcome in pregnant substance users. Journal of Substance Abuse Treatment 2008, 35:161-173.
52. Woody G.E., Poole S.A., Subramaniam G., Dugosh K., Bogenschutz M., Abbott P., et al. Extended vs. short-term buprenorphine/naloxone for treatment of opioid-addicted youth: A randomized trial. Journal of the American Medical Association 2008, 300:2003-2011.